Olena Mandrik

MSc Maastricht (the Netherlands), PhD Rotterdam (the Netherlands)

Population Health, School of Medicine and Population Health

Research Fellow

o.mandrik@sheffield.ac.uk
+44 114 222 6392

Regent Court (ScHARR)

Full contact details

Olena Mandrik
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA

Profile: I joined HEDS as a modeller in October 2018 after two-year post-doctoral fellowship in the International Agency for Research on Cancer of the World Health Organization. Prior to this I was employed by the Erasmus University Rotterdam, School of Health Policy and Management, were earlier (2015) I defended my PhD. My path to science was long, and I have a seven-year experience in pharmaceutical business organizations. Starting from Manager in Pharmacoeconomics and growing to the Head of the Market Access Department, I was employed by such global companies as Janssen-Cilag, Merck, and Sanofi. Within HEDS I specialise in public health-related modelling projects, focussing particularly upon modelling of cancer prevention and early detection.

Research interests

Cancer prevention and early detection
Calibration of cancer natural history disease models
Implementation research
Global research

Current projects

I currently work on a microsimulation model for colorectal cancer

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Mandrik O, Thomas C & Chilcott J (2024) Development of the Microsimulation Model in Cancers of Bladder and Kidney (MiMiC-BlaKy). HEDS Discussion Paper Series(24.03). View this article in WRRO
Catto JWF, North B, Goff M, Carter A, Sleeth M, Mandrik O, Chilcott J, Sasieni P & Cumberbatch MGK (2023) Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk. BMJ Open, 13(9). View this article in WRRO
Mandrik O, Roitberg F, Lauby-Secretan B, Parak U, Ramadas K, Varenne B, Sankaranarayanan R & Carvalho AL (2023) Perspective on oral cancer screening: time for implementation research and beyond. Journal of Cancer Policy, 35.
Bouvard V, Nethan ST, Singh D, Warnakulasuriya S, Mehrotra R, Chaturvedi AK, Chen TH-H, Ayo-Yusuf OA, Gupta PC, Kerr AR , Tilakaratne WM et al (2022) IARC perspective on oral cancer prevention. New England Journal of Medicine.
Parak U, Lopes Carvalho A, Roitberg F & Mandrik O (2022) Effectiveness of screening for oral cancer and oral potentially malignant disorders (OPMD): a systematic review. Preventive Medicine Reports, 30, 101987-101987.
Lourenção M, Simões Correa Galendi J, Galvão HDCR, Antoniazzi AP, Grasel RS, Carvalho AL, Mauad EC, Oliveira JHCD, Reis RM, Mandrik O & Palmero EI (2022) Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies : using real-world data from an upper-middle income country. Frontiers in Oncology, 12.
Thomas C, Mandrik O & Whyte S (2022) Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England. Preventive Medicine. View this article in WRRO
Mandrik O, Fotheringham J, Ren S, Tice JA, Chapman RH, Stevenson MD, Pearson SD, Herron-Smith S, Agboola F & Thokala P (2022) The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology, 17(3), 385-394.
Tice JA, Mandrik O, Thokala P, Fotheringham J & Pearson SD (2021) The effectiveness and value of belimumab and voclosporin for lupus nephritis.. Journal of Managed Care & Specialty Pharmacy, 27(10), 1495-1499.
Daubner-Bendes R, Kovács S, Niewada M, Huic M, Drummond M, Ciani O, Blankart CR, Mandrik O & Kaló Z (2021) Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges. Frontiers in Public Health.
Escriva-Boulley G, Mandrik O, Préau M, Herrero R & Villain P (2020) Cognitions and behaviours of general practitioners in France regarding HPV vaccination : a theory-based systematic review. Preventive Medicine.
Isah AUJ, Ekwunife OI, Ejie IL & Mandrik O (2020) Effects of nutritional supplements on the re-infection rate of soil-transmitted helminths in school-age children : a systematic review and meta-analysis. PLoS ONE, 15(8). View this article in WRRO
Mandrik O, Tolma E, Zielonke N, Meheus F, Ordóñez-Reyes C, Severens H & Murillo R (2020) Systematic reviews as a “lens of evidence”: determinants of participation in breast cancer screening. Journal of Medical Screening. View this article in WRRO
Mandrik O, Yaumenenka A, Herrero R & Jonker M (2019) Population preferences for breast cancer screening policies : discrete choice experiment in Belarus. PLoS ONE, 1. View this article in WRRO
Mandrik O, Ekwunife O, Meheus F, Severens JL, Lhachimi S, Uyl-de Groot CA & Murillo R (2019) Systematic reviews as a “lens of evidence”: determinants of cost-effectiveness of breast cancer screening. Cancer Medicine. View this article in WRRO
Mandrik O, Zielonke N, Meheus F, Severens H, Guha N, Herrero R & Murillo R (2019) Systematic reviews as a “lens of evidence”: determinants of benefits and harms of breast cancer screening. International Journal of Cancer, 145(4), 994-1006. View this article in WRRO
Lin L, Severens JL & Mandrik O (2019) Disutility associated with cancer screening programs : a systematic review. PLoS ONE, 14(7). View this article in WRRO
Mandrik O, Ekwunife OI, Zielonke N, Meheus F, Severens JL, Lhachimi SK & Murillo R (2017) What determines the effects and costs of breast cancer screening? A protocol of a systematic review of reviews. Systematic Reviews, 6(1).
Mandrik O, Knies S, Golubovska О, Duda O, Dudar L, Fedorchenko S, Zaliska О & Severens JLH (2015) Cost comparison of treating chronic hepatitis C genotype one with pegylated interferons in Ukraine. Open Medicine, 10(1).
Mandrik O, Knies S, Kalo Z & Severens JL (2015) REVIEWING TRANSFERABILITY IN ECONOMIC EVALUATIONS ORIGINATING FROM EASTERN EUROPE. International Journal of Technology Assessment in Health Care, 31(6), 434-441.
Mandrik O, Knies S, Kaló Z & Severens JL (2014) Transferability of Economic Evaluations To Central and Eastern Euroepan and Former Soviet Countries. Value in Health, 17(7), A443-A444.
Mandrik O, Corro Ramos I, Zalis’ka O, Gaisenko A & Severens JL (2013) Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine. Value in Health Regional Issues, 2(2), 205-209.
Zalis'ka O & Mandrik O (2010) PSS14 PHARMACOECONOMICS OF INNOVATIVE MEDICINES FOR TREATMENT OF PSORIASIS IN UKRAINE. Value in Health, 13(7), A400-A400.
Chanakira EZ, Thomas CV, Balen J & Mandrik O () A systematic review of public health interventions to address breast cancer inequalities in low- and middle-income countries. Systematic Reviews, 13(1).
Mandrik O, Hahn AI, Catto JWF, Zauber AG, Cumberbatch M & Chilcott J () Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review. PharmacoEconomics.
Catto JWF, Mandrik O, Quayle LA, Hussain SA, McGrath J, Cresswell J, Birtle AJ, Jones RJ, Mariappan P, Makaroff LE , Knight A et al () Diagnosis, treatment and survival from bladder, upper urinary tract and urethral cancers: Real world findings from NHS England between 2013 and 2019. BJU International.
Mandrik O, Chilcott J & Thomas C () Modelling the impact of the coronavirus pandemic on bowel cancer screening outcomes in England: a decision analysis to prepare for future screening disruption. Preventive Medicine.
Thomas C, Mandrik O, Whyte S, Saunders C, Griffin S & Usher-Smith J () Should colorectal cancer screening start at different ages for men and women? Cost-effectiveness analysis for a resource constrained service. Cancer Reports.
Mandrik O, Corro Ramos I, Knies S, Al M & Severens JH () Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine. Cancer Management and Research, 279-279.
Mandrik O, Knies S & Severens JH () Economic value of in vitro fertilization in Ukraine, Belarus, and Kazakhstan. ClinicoEconomics and Outcomes Research, 347-347.
Mandrik O, Mankovsky B, Doroshenko O, Pan'kiv V, Kravchun N, Vlasenko M, Hulchiy M, Baljuk M, Komisarenko Y, Martsynik E , Sokolova L et al () Impact of hypoglycemia on daily life of type 2 diabetes patients in Ukraine. Journal of Multidisciplinary Healthcare, 249-249.
Mandrik O, Severens JL, Bardach A, Ghabri S, Hamel C, Mathes T, Vale L, Wisløff T & Goldhaber-Fiebert JD () Critical Appraisal of Systematic Reviews with Costs and Cost-effectiveness Outcomes: an ISPOR Good Practices Task Force Report. Value in Health.
Thomas C, Mandrik O, Saunders CL, Thompson D, Whyte S, Griffin S & Usher-Smith JA () The costs and benefits of risk-stratification for colorectal cancer screening based on phenotypic and genetic risk: a health economic analysis. Cancer Prevention Research, canprevres.0620.2020-canprevres.0620.2020.
Mandrik O, Thomas C, Whyte S & Chilcott J () CALIBRATING NATURAL HISTORY OF CANCER MODELS IN THE PRESENCE OF DATA INCOMPATIBILITY; PROBLEMS AND SOLUTIONS. PharmacoEconomics.

Conference proceedings papers

Mandrik O, Zalis'ka O & Severens J (2012) PCN103 How Much Price Component is Accounted for in State Drugs Purchase Decisions in Ukrainian Oncology?. Value in Health, Vol. 15(7) (pp A428-A428)
Mandrik O, Zalis'ka O & Severens JL (2012) PCN77 Cost-Effectiveness Analysis of Rituximab Use in Treatment of Chronic Lymphocytic Leukemia in Ukraine. Value in Health, Vol. 15(4) (pp A221-A221)
Pariy V, Stepanenko A, Mandrik O & Zalis'ka O (2012) PHP106 Priority Setting for Health Technology Assessment in Ukraine. Value in Health, Vol. 15(4) (pp A32-A32)
Mandrik O, Severens JL, Zalis'ka O, Doroshenko O, Maynych Y & Tolubaiev V (2012) PHP86 Analysis of Factors Influencing Drugs Prescription Decision Making in Ukraine. Value in Health, Vol. 15(4) (pp A28-A28)
Mandrik O, Zalis'ka O & Severens JL (2011) PCN57 Cost of Treatment of Multiple Myeloma in Ukraine. Value in Health, Vol. 14(7) (pp A444-A444)
Mandrik O & Zalis'ka O (2011) PCN49 THE RELATIONSHIP OF AGE AND SEX WITH COST OF TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE. Value in Health, Vol. 14(3) (pp A163-A163)

Datasets

Mandrik O, Yaumenenka A, Herrero R & Jonker MF BELA: evaluation of population preferences to breast cancer screening in Belarus.

Preprints

Mandrik O, Thomas C, Strong M & Whyte S (2021) Calibration and Validation of the Microsimulation Model in Cancer of the Bowel (MiMiC-Bowel), an Individual Patient Simulation Model for Investigation of the Cost-effectiveness of Personalised Screening and Surveillance Strategies.. View this article in WRRO